EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adipokine-Based Therapeutics for MASLD: Bridging Adipokine Resistance and FGF21 Half-Life Extension Strategies

Reeju Amatya, Yassmine Benmokadem, Ji Yeon Hyun, Kyoung Ah Min, Meong Cheol Shin

Livers · 01.11.2026 · 6 (6) · 111

DOI: 10.3390/livers6060111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Livers, online erschienen am 01.11.2026. Verfasst von Reeju Amatya und 4 weiteren Autor:innen. Die Arbeit nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education (MOE) and the Gyeongsangnam-do, Republic of Korea, Ministry of Food and Drug Safety.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) arises from the convergence of hepatic lipid overload, insulin resistance, mitochondrial dysfunction, oxidative stress, and chronic low-grade inflammation, yet effective pharmacotherapy remains limited. Increasingly, adipose tissue is recognized not as a passive lipid depot but as an endocrine organ whose secreted adipokines regulate hepatic lipid and glucose metabolism, inflammatory signaling, and fibrogenesis through pathways including AMP-activated protein kinase (AMPK), peroxisome proliferator–activated receptor-α (PPARα), protein kinase B (Akt), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Restoring adipokine activity can reduce hepatic triglyceride levels, enhance fatty acid β-oxidation, improve insulin sensitivity, and attenuate fibrotic remodeling, but the translational maturity of individual targets varies considerably. Among these, only the fibroblast growth factor 21 (FGF21) programme can currently be described as clinically advanced, having reached Phase 2b/3 human trials; adiponectin remains the most mechanistically characterized hepatoprotective adipokine, but adiponectin-directed agents (adiponectin receptor (AdipoR) agonists, adiponectin mimetics) are still preclinical. Two interlocking barriers separate this biological rationale from durable therapeutic application: adipokine resistance, which appears to be a systemic feature of advanced disease that blunts signaling across multiple axes, and the short plasma half-lives and proteolytic susceptibility of native adipokines. This review examines the molecular mechanisms, pharmacokinetics, and receptor-sensitization strategies relevant to adipokine-based therapy, including PEGylation, glycoPEGylation, fragment crystallizable (Fc)-fusion, and rational combination regimens, positioning adipokine-targeted therapy as an attractive approach to MASLD treatment.

Förderung

  • National Research Foundation of Korea
  • Ministry of Education (MOE) and the Gyeongsangnam-do, Republic of Korea
  • Ministry of Food and Drug Safety
  • Gyeongnam Anti-aging Research Institute

Zitieren

APA

Amatya, R., Benmokadem, Y., Hyun, J. Y., Min, K. A., & Shin, M. C. (2026). Adipokine-Based Therapeutics for MASLD: Bridging Adipokine Resistance and FGF21 Half-Life Extension Strategies. Livers, 6(6), 111. https://doi.org/10.3390/livers6060111

Vancouver

Amatya R, Benmokadem Y, Hyun JY, Min KA, Shin MC. Adipokine-Based Therapeutics for MASLD: Bridging Adipokine Resistance and FGF21 Half-Life Extension Strategies. Livers. 2026;6(6):111. doi:10.3390/livers6060111

BibTeX
@article{Amatya2026,
  author = {Amatya, Reeju and Benmokadem, Yassmine and Hyun, Ji Yeon and Min, Kyoung Ah and Shin, Meong Cheol},
  title = {Adipokine-Based Therapeutics for MASLD: Bridging Adipokine Resistance and FGF21 Half-Life Extension Strategies},
  journal = {Livers},
  year = {2026},
  volume = {6},
  number = {6},
  pages = {111},
  doi = {10.3390/livers6060111}
}
Kostenlos starten →